Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
about
Colitis-associated colon cancer: Is it in your genes?Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab.Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencingThe somatic genomic landscape of glioblastomaExploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number dataEGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing.Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinomaConstitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.Effect and Mechanism of Total Flavonoids Extracted from Cotinus coggygria against Glioblastoma Cancer In Vitro and In VivoTargeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.Role of Biomarkers in the Clinical Management of Glioblastomas: What are the Barriers and How Can We Overcome Them?Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6Inhibition of DHHC20-Mediated EGFR Palmitoylation Creates a Dependence on EGFR Signaling.EGFR Fusions as Novel Therapeutic Targets in Lung CancerA survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival.Pre-diagnostic serum levels of EGFR and ErbB2 and genetic glioma risk variants: a nested case-control study.Anti-cancer Therapies in High Grade Gliomas.Canine pulmonary adenocarcinoma tyrosine kinase receptor expression and phosphorylation.Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge.High-resolution deep imaging of live cellular spheroids with light-sheet-based fluorescence microscopy.Erlotinib: early clinical development in brain cancer.Molecular pathologic diagnosis of epidermal growth factor receptor.Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates.Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma.Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers.Multigene profiling to identify alternative treatment options for glioblastoma: a pilot study.Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The "Rotation Model".Inhibitory Kinetics and Mechanism of Flavonoids Extracted from Cotinus coggygria Scop. Against Glioblastoma Cancer.EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise.Something Old, Something New, Something Borrowed, Something Fused: Novel EGFR Rearrangements in Lung Adenocarcinomas.Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerizationCurrent trends in mouse models of glioblastoma.Autophosphorylation of the C-terminal domain is not required for oncogenic transformation by lung-cancer derived EGFR mutants.
P2860
Q26778018-8A9D485A-DF9D-4FF2-B571-23D2466D6DF0Q27853014-254B269F-2219-432E-A445-6F81B25D2FBAQ27853175-252DF235-09E1-4E01-AF82-37DB4A9C3111Q28275103-B4E4D082-570B-4133-8C96-8358E5F44DFEQ28300185-E47E30D9-E157-4729-AB04-1C22BEB778E0Q30699293-40CFCCE3-4502-4217-AC0C-A8B1EAFAAF39Q34016908-1E74D7C8-AB3C-4092-B1FE-9B476918E300Q34172448-3B02929D-5312-4D80-92A8-E5765FE70FD0Q35832237-1EB01A84-4514-4A94-9A0F-8CA665659945Q36236420-BC7506F4-6C8F-435B-B401-27BEE306A248Q36297064-EC9BC29C-E48F-4E69-8151-7121102D0EB8Q36542980-ACEDD563-2F3F-426C-B81A-928549F747DBQ36683851-E06DE8B1-CC5A-451D-A47A-F89A5EB1864EQ36880844-2D4262EB-83F9-40D5-869E-DEED64C33EE6Q36971209-7277DDB2-754A-44F0-9E14-88A9C98D200FQ37019200-7D0E10E0-F98D-498F-A024-A5D4DA549D3EQ37208166-301489D3-4090-4CD5-94D6-02A3C8F7A0B2Q37290626-F485C1AE-2303-49AB-A31A-04B9B8EFCD04Q37496847-33D3F4EC-9E96-4E26-B276-3A762C523162Q37729676-640FE4AA-6965-445D-8AE0-B13F1DEEE758Q38084845-8A9093C1-EC9B-40F8-B620-6B7CE36BB0E1Q38212394-94FBAFCF-F95C-4CED-AAC2-3B0EF0C6263CQ38262472-34837D79-058C-4CAC-9B4A-C0269D16CC6CQ38722183-322B1C4E-8804-4880-9D82-FCA67AA09374Q38778367-6CFADA08-EEC2-42E0-83EE-F0B2CAD4DB5EQ38835146-08C96779-39AF-4820-8FC3-D0FFA08E3A09Q39217123-D095E01D-A660-48C6-9C1A-95AD177FBEE9Q39346046-7F07E4F7-46DF-473D-AF24-05378BDC8118Q39347456-2E70A910-4A68-4162-AB58-AC4A63A5B36CQ40089704-0F212D92-66EC-4E4E-8E54-02953CBC4695Q41815028-4565393F-0FE4-4C80-A16A-6271C87F1EB4Q41894424-92FBA28F-E6BD-469B-AF85-AE8B6013BAA6Q47169542-1ED81727-7A0F-4779-860B-5399A47E0CFFQ49720489-511511D4-F12E-42D4-9965-A4C2142CEF3F
P2860
Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Glioblastoma-derived epidermal ...... ve to EGFR-directed therapies.
@ast
Glioblastoma-derived epidermal ...... ve to EGFR-directed therapies.
@en
type
label
Glioblastoma-derived epidermal ...... ve to EGFR-directed therapies.
@ast
Glioblastoma-derived epidermal ...... ve to EGFR-directed therapies.
@en
prefLabel
Glioblastoma-derived epidermal ...... ve to EGFR-directed therapies.
@ast
Glioblastoma-derived epidermal ...... ve to EGFR-directed therapies.
@en
P2093
P2860
P1433
P1476
Glioblastoma-derived epidermal ...... ve to EGFR-directed therapies.
@en
P2093
Andrew D Cherniack
Derek Chiang
Hideo Watanabe
Jeonghee Cho
Jihyun Kwon
Robert C Onofrio
Roel Verhaak
Sandra Pastorino
P2860
P304
P356
10.1158/0008-5472.CAN-11-0821
P407
P577
2011-10-14T00:00:00Z